Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210039 · ClinicalTrials.gov registry record · NA
Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02210039: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02210039 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02210039, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The study is being done to test the feasibility and tolerability of a SECM imaging probe in patients with Barrett's Esophagus (BE). Subjects will undergo SECM probe imaging while they are under conscious sedation. Spiral SECM imaging will be performed continuously over a pre-determined length. Patients will later be asked for their feedback.
Interventions
- DEVICE SECM Probe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210039
The ClinicalTrials.gov registry entry for NCT02210039 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SECM Probe is the first listed.
NCT02210039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02210039 about?
NCT02210039 is a clinical study titled "Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe". The study is being done to test the feasibility and tolerability of a SECM imaging probe in patients with Barrett's Esophagus (BE). Subjects will undergo SECM probe imaging while they are under conscious sedation. Spiral SECM imaging will be performed continuously over a pre-determined length. Pati...
What is the current status of trial NCT02210039?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02210039?
The interventions under investigation include: SECM Probe (DEVICE).
Who is sponsoring clinical trial NCT02210039?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.